1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Papillomavirus Infection: new trials by email Literature Review of Papillomavirus Infection trials Research Report on Papillomavirus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-11-02 | 2026-10-28 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
Papillomavirus Infections (2) · Abdominal Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Epstein-Barr Virus Infections (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Genital Neoplasms, Female (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1)
Communicable Diseases (2) · DNA Virus Infections (2) · Disease Attributes (2) · Genital Diseases (2) · Infections (2) · Otorhinolaryngologic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2) · Thoracic Neoplasms (2) · Tumor Virus Infections (2) · Urogenital Diseases (2) · Virus Diseases (2)
Bevacizumab (1) · Docetaxel (1) · Irinotecan (1)
Marengo Therapeutics, Inc. (1) · National Cancer Institute (NCI) (1)
United States (2) · Canada (1) · France (1) · Spain (1)
2023 (1)